Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice

World Journal of Gastroenterology

Volumn 22, Issue 8, 2016, Pages 2512-2523

  Yamamoto, Takaya ^a   Nakade, Yukiomi ^a   Yamauchi, Taeko ^a   Kobayashi, Yuji ^a   Ishii, Norimitsu ^a   Ohashi, Tomohiko ^a   Ito, Kiyoaki ^a   Sato, Ken ^a   Fukuzawa, Yoshitaka ^a   Yoneda, Masashi ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Free fatty acid; Glucagon like peptide 1; Kupffer cells; Nonalcoholic steatohepatitis; Oxidative stress

Indexed keywords

ACYL COENZYME A OXIDASE; ALANINE AMINOTRANSFERASE; EXENDIN 4; FATTY ACID; FATTY ACID TRANSPORTER 4; GLUCOSE; IMMUNOREACTIVE INSULIN; LIVER TRIACYLGLYCEROL LIPASE; MALONALDEHYDE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; AUTACOID; BIOLOGICAL MARKER; FATTY ACID TRANSPORTER; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; SLC27A4 PROTEIN, MOUSE; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; VENOM;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; KUPFFER CELL; MACROPHAGE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER; MALE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; NONOBESE DIABETIC MOUSE; PATHOLOGY; TIME FACTOR;

ACYL-COA OXIDASE; ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; FATTY ACID TRANSPORT PROTEINS; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; INFLAMMATION MEDIATORS; LIVER; MACROPHAGES; MALE; MICE, INBRED NOD; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PEPTIDES; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TIME FACTORS; TRIGLYCERIDES; VENOMS;

EID: 84959923383     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i8.2512     Document Type: Article

References (32)

1. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104: 861-867 [PMID: 19293782 DOI: 10.1038/ajg.2009.67]
2. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16, vii [PMID: 17544968 DOI: 10.1016/j.cld.2007.02.009]
3. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, Kim KR, Lee HC, Huh KB, Cha BS. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164: 2169-2175 [PMID: 15505132 DOI: 10.1001/archinte.164.19.2169]
4. Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, Bhattacharya B, Bhattacharya D, Manna B, Dhali GK, Santra A, Chowdhury A. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51: 1593-1602 [PMID: 20222092 DOI: 10.1002/hep.23567]
5. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzymealtered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2004; 315: 187-195 [PMID: 15013444 DOI: 10.1016/j.bbrc.2004.01.038]
6. Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, Kanayama M, Oya T, Morita S, Sasahara M, Mann DA, Sugiyama T. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int 2009; 29: 988-996 [PMID: 19386026 DOI: 10.1111/j.1478-3231.2009.02006.x]
7. Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25: 152-156 [PMID: 18201212 DOI: 10.1111/j.1464-5491.2007.02333.x]
8. Klinger S, Poussin C, Debril MB, Dolci W, Halban PA, Thorens B. Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. Diabetes 2008; 57: 584-593 [PMID: 18025410 DOI: 10.2337/db07-1414]
9. Perusicová J. [Incretin strategy in the treatment of type 2 diabetes mellitus-DPPIV]. Vnitr Lek 2007; 53: 1005-1009 [PMID: 18019673]
10. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268: 19650-19655 [PMID: 8396143]
11. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, Egan JM. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936-1941 [PMID: 10830274]
12. Tang-Christensen M, Cowley MA. GLP-1 analogs: satiety without malaise? Am J Physiol Regul Integr Comp Physiol 2007; 293: R981-R982 [PMID: 17596320 DOI: 10.1152/ajpregu.00449.2007]
13. Nakade Y, Tsukamoto K, Iwa M, Pappas TN, Takahashi T. Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats. Auton Neurosci 2007; 131: 50-56 [PMID: 16938493 DOI: 10.1016/j.autneu.2006.06.007]
14. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-181 [PMID: 16374859 DOI: 10.1002/hep.21006]
15. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2012; 302: G762-G772 [PMID: 22268099 DOI: 10.1152/ajpgi.00476.2011]
16. Wang Y, Parlevliet ET, Geerling JJ, van der Tuin SJ, Zhang H, Bieghs V, Jawad AH, Shiri-Sverdlov R, Bot I, de Jager SC, Havekes LM, Romijn JA, Willems van Dijk K, Rensen PC. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol 2014; 171: 723-734 [PMID: 24490861 DOI: 10.1111/bph.12490]
17. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1035-G1043 [PMID: 15256362 DOI: 10.1152/ajpgi.00199.2004]
18. Tanaka N, Takahashi S, Fang ZZ, Matsubara T, Krausz KW, Qu A, Gonzalez FJ. Role of white adipose lipolysis in the development of NASH induced by methionine-and choline-deficient diet. Biochim Biophys Acta 2014; 1841: 1596-1607 [PMID: 25178843 DOI: 10.1016/j.bbalip.2014.08.015]
19. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-495 [PMID: 8608603]
20. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 2008; 49: 1068-1076 [PMID: 18227531 DOI: 10.1194/jlr.M800042-JLR200]
21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701]
22. Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, Aso K, Kanamori H, Ohashi T, Sato K, Nakao H, Haneda M, Yoneda M. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol 2013; 48: 491-503 [PMID: 22886508 DOI: 10.1007/s00535-012-0651-7]
23. Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, Endo H, Takahashi H, Inamori M, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 2009; 50: 772-780 [PMID: 19650159 DOI: 10.1002/hep.23094]
24. Barter PJ, Nestel PJ. Precursors of plasma triglyceride fatty acids in obesity. Metabolism 1973; 22: 779-783 [PMID: 4350847]
25. Doege H, Stahl A. Protein-mediated fatty acid uptake: novel insights from in vivo models. Physiology (Bethesda) 2006; 21: 259-268 [PMID: 16868315 DOI: 10.1152/physiol.00014.2006]
26. Jha P, Knopf A, Koefeler H, Mueller M, Lackner C, Hoefler G, Claudel T, Trauner M. Role of adipose tissue in methioninecholine-deficient model of non-alcoholic steatohepatitis (NASH). Biochim Biophys Acta 2014; 1842: 959-970 [PMID: 24594481 DOI: 10.1016/j.bbadis.2014.02.012]
27. Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, Akisawa N, Saibara T, Hiroi M, Enzan H, Onishi S. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004; 40: 781-786 [PMID: 15094225 DOI: 10.1016/j.jhep.2004.01.028]
28. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004; 40: 386-393 [PMID: 15368443 DOI: 10.1002/hep.20302]
29. Fox ES, Brower JS, Bellezzo JM, Leingang KA. N-acetylcysteine and alpha-tocopherol reverse the inflammatory response in activated rat Kupffer cells. J Immunol 1997; 158: 5418-5423 [PMID: 9164963]
30. Rollins BJ. Chemokines. Blood 1997; 90: 909-928 [PMID: 9242519]
31. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-568 [PMID: 9560152 DOI: 10.1038/33340]
32. Park S, Hong SM, Ahn IS. Exendin-4 and exercise improve hepatic glucose homeostasis by promoting insulin signaling in diabetic rats. Metabolism 2010; 59: 123-133 [PMID: 19766272 DOI: 10.1016/j.metabol.2009.06.026]